{"id":47213,"date":"2022-08-11T22:02:03","date_gmt":"2022-08-11T20:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/"},"modified":"2022-08-11T22:02:03","modified_gmt":"2022-08-11T20:02:03","slug":"amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/","title":{"rendered":"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n\u02d7 <i>ALBRIOZA\u2122 (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx<\/i>\n<\/p>\n<p class=\"bwalignc\">\n\u02d7 <i>FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial team now launch ready<\/i>\n<\/p>\n<p class=\"bwalignc\">\n\u02d7 <i>Marketing Authorisation Application under review and preparations underway for commercialization of AMX0035 in the European Union<\/i>\n<\/p>\n<p>CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (\u201cAmylyx\u201d or the \u201cCompany\u201d) today reported financial results for the quarter ended June 30, 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/5\/13268_Amylyx_logo_notagline-Color.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/21\/13268_Amylyx_logo_notagline-Color.jpg\"><\/a><\/p>\n<p>\n\u201cThe second quarter of 2022 has been another exciting time for Amylyx, marked by our first regulatory approval. ALBRIOZA\u2122 is now commercially available in Canada, signifying an important milestone on our path to helping people living with ALS,\u201d said Justin Klee, Co-CEO of Amylyx.\n<\/p>\n<p>\nJosh Cohen, Co-CEO of Amylyx, added, \u201cLooking ahead, we remain committed to advancing our ongoing regulatory interactions and preparing for launch in the U.S. and the European Union, if approved.\u201d\n<\/p>\n<p>\n<b>Second Quarter 2022 and Recent Business Highlights:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Announced Health Canada approval of ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). <\/b>This decision was the first marketing approval issued to Amylyx worldwide. Commercial launch of ALBRIOZA (also known as AMX0035) commenced on July 29, 2022, in Canada.<\/p>\n<\/li>\n<li>\n<b>Regulatory applications under review for AMX0035 for the treatment of ALS in the U.S. and the European Union.<\/p>\n<p><\/b><\/p>\n<ul class=\"bwlistcircle\">\n<li>\n<i>New Drug Application (NDA) for AMX0035 for the treatment of ALS under Priority Review by the U.S. Food and Drug Administration (FDA).<\/i> The FDA will reconvene the Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) on September 7, 2022, with discussions focused on the additional analyses of data from the Company\u2019s clinical studies that were determined by the FDA to constitute a major amendment to the NDA. The Prescription Drug User Fee Act (PDUFA) action date is September 29, 2022.<\/p>\n<\/li>\n<li>\n<i>Marketing Authorisation Application for AMX0035 for the treatment of ALS under review with European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP).<\/i> The review process is proceeding as expected, with receipt of the Day 120 List of Questions following the June CHMP meeting. Amylyx will continue to work with EMA through its review process, and the Company expects a decision in the first half of 2023. Preparations are underway for commercialization of AMX0035 in the European Union, if approval is received.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<b>Announced planned open-label extension (OLE) phase for Phase 3 PHOENIX trial in ALS at the 17<sup>th<\/sup> International Congress on Neuromuscular Diseases (ICNMD 2022). <\/b>The poster included an overview of the global Phase 3 PHOENIX trial design and methodology, as well as an update on a planned OLE phase for PHOENIX, and was presented on July 9, 2022, in Brussels, Belgium.<\/p>\n<\/li>\n<li>\n<b>Announced presentation of new analysis of CENTAUR trial results at the European Network to Cure ALS (ENCALS) 2022.<\/b> A new post hoc analysis measuring substantial individual response to AMX0035 compared to placebo continues to demonstrate the efficacy of the combination and was presented in Edinburgh, Scotland on June 2, 2022.<\/p>\n<\/li>\n<li>\n<b>Announced publication of data showing lower occurrence of tracheostomy\/permanent assisted ventilation (PAV) and delayed first hospitalization in peer-reviewed medical journal, <i>Journal of Neurology, Neurosurgery, and Psychiatry<\/i><\/b><i>. <\/i>The analyses of data from the Phase 2 CENTAUR trial showed that randomization to AMX0035 resulted in a lower risk of occurrence of death or tracheostomy\/PAV by 49% and first hospitalization by 44% over the course of the Phase 2 trial and duration of follow-up. As of the analysis cutoff with the longest follow up of 35 months, median time to first hospitalization was not yet reached in the group originally randomized to AMX0035, compared with 14.1 months in the group originally randomized to placebo.<\/p>\n<\/li>\n<li>\n<b>Announced publication of new analyses from the CENTAUR trial, further demonstrating significant survival benefit of AMX0035 in peer-reviewed medical journal, <i>Muscle &amp; Nerve<\/i>. <\/b>A post hoc analysis using the rank-preserving structural failure time model (RPSFTM), a method frequently employed in oncology to account for placebo crossover, estimated a 10.6-month longer median survival duration for participants originally randomized to AMX0035 than participants originally randomized to placebo. In addition, participants randomized to receive AMX0035 and who continued into the OLE phase showed an 18.8-month longer median survival duration than participants who never received AMX0035 in a subgroup analysis.\n<\/li>\n<\/ul>\n<p>\n<b>Financial Results for the Second Quarter Ended June 30, 2022<\/b>\n<\/p>\n<p>\nFor the quarter ended June 30, 2022, research and development expenses were $24.3 million, compared to $10.9 million for the quarter ended June 30, 2021. The increase was mainly driven by higher product manufacturing and development expenses in support of clinical trial and launch preparation activities for commercialization, and increased personnel-related expenses due to increased headcount to support research and development efforts.\n<\/p>\n<p>\nGeneral and administrative expenses were $30.0 million for the quarter ended June 30, 2022, compared to $7.7 million for the quarter ended June 30, 2021. The increase was primarily due to higher personnel-related expenses due to increased headcount to support launch preparation initiatives and increased consulting and professional services fees for commercial readiness activities and operations as a public company.\n<\/p>\n<p>\nNet loss for the quarter ended June 30, 2022, was $54.1 million, or $0.93 per share, compared to a net loss of $21.9 million, or $3.41 per share, for the same period in 2021.\n<\/p>\n<p>\nCash, cash equivalents and short-term investments were $206.7 million at June 30, 2022, compared to $255.2 million at March 31, 2022.\n<\/p>\n<p>\n<b>About AMX0035<\/b>\n<\/p>\n<p>\nAMX0035 (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication approved with conditions as ALBRIOZA\u2122 to treat amyotrophic lateral sclerosis (ALS) in Canada and with marketing applications pending in the United States and the European Union. The combination of sodium phenylbutyrate and taurursodiol may reduce neuronal cell death, hypothesized to occur by simultaneously mitigating endoplasmic reticulum (ER) stress and mitochondrial dysfunction. AMX0035 is also being explored for the potential treatment of other neurodegenerative diseases.\n<\/p>\n<p>\n<b>About the CENTAUR Trial<\/b>\n<\/p>\n<p>\nCENTAUR was a multicenter Phase 2 clinical trial in 137 participants with ALS encompassing a 6-month randomized placebo-controlled phase and an open-label long-term follow-up phase. The trial met its primary efficacy endpoint of reducing functional decline as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale \u2013 Revised (ALSFRS-R).\n<\/p>\n<p>\nOverall, reported rates of adverse events and discontinuations were similar between AMX0035 and placebo groups during the 24-week randomized phase; however, gastrointestinal events occurred with greater frequency (\u22652%) in the AMX0035 group. Detailed safety and functional efficacy data from CENTAUR were published in the <i>New England Journal of Medicine<\/i>. Data from additional analyses from the CENTAUR trial were published in <i>Muscle &amp; Nerve<\/i> in 2020 and 2022, and the <i>Journal of Neurology, Neurosurgery and Psychiatry<\/i> in 2022.\n<\/p>\n<p>\nThe CENTAUR trial was funded, in part, by the ALS ACT grant and the ALS Ice Bucket Challenge, and was supported by The ALS Association, ALS Finding a Cure (a program of The Leandro P. Rizzuto Foundation), the Northeast ALS Consortium, and the Sean M. Healey &amp; AMG Center for ALS at Mass General.\n<\/p>\n<p>\n<b>About the PHOENIX Trial<\/b>\n<\/p>\n<p>\nThe Phase 3 PHOENIX clinical trial (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05021536%3Fterm%3DNCT05021536%26draw%3D2%26rank%3D1&amp;esheet=52807486&amp;newsitemid=20220811005026&amp;lan=en-US&amp;anchor=NCT05021536&amp;index=1&amp;md5=6e284feec718c59cc7018752c5037674\" rel=\"nofollow noopener\" shape=\"rect\">NCT05021536<\/a>) is a 48-week, randomized placebo-controlled global clinical trial further evaluating the safety and efficacy of AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of ALS. The primary efficacy outcome of the trial will be a composite measure of survival and Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score progression over 48 weeks and survival and tolerability over 48 weeks. Secondary endpoints include change in slow vital capacity (SVC), measured both at home using a self-administered spirometer to support virtual data collection and at clinic sites using standard spirometry, quality of life patient-reported outcome assessments, ventilation-free survival rates and other measures. More information on the PHOENIX trial can be found at www.clinicaltrials.gov and eudract.ema.europa.eu.\n<\/p>\n<p>\n<b>About Amylyx Pharmaceuticals<\/b>\n<\/p>\n<p>\nAmylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada and EMEA. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Famylyx.com&amp;esheet=52807486&amp;newsitemid=20220811005026&amp;lan=en-US&amp;anchor=amylyx.com&amp;index=2&amp;md5=b0e963883e6df9f2886a71f2ad36f825\" rel=\"nofollow noopener\" shape=\"rect\">amylyx.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Famylyx&amp;esheet=52807486&amp;newsitemid=20220811005026&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=2a4148d7472b1d24f630078a3c984c82\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAmylyxPharma&amp;esheet=52807486&amp;newsitemid=20220811005026&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=bad47e28c2995a416e273439c3e78656\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>. For investors, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.amylyx.com&amp;esheet=52807486&amp;newsitemid=20220811005026&amp;lan=en-US&amp;anchor=investors.amylyx.com&amp;index=5&amp;md5=a3e7148bb80a00f4e7879488de4a88ce\" rel=\"nofollow noopener\" shape=\"rect\">investors.amylyx.com<\/a>.\n<\/p>\n<p>\n<b>Forward-Looking Statements<\/b>\n<\/p>\n<p>\nStatements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Amylyx\u2019 strategy, business plans and objectives for 2022 and beyond; the potential of AMX0035 as a treatment for ALS, the efficacy and safety profile of AMX0035 and the potential for regulatory approval of AMX0035 as a treatment for ALS in the U.S. and the European Union and to maintain approval in Canada; the commercialization of ALBRIOZA in Canada and potential commercial launch of AMX0035 as a treatment for ALS in other jurisdictions, if approved, and the ability to scale operations to prepare for commercial launch; the timing, progress and results of our global Phase 3 PHOENIX clinical trial of AMX0035 and potential OLE extension; the potential of AMX0035 or other future therapeutic candidates as a treatment for neurodegenerative diseases generally; and expectations regarding our longer-term strategy. Any forward-looking statements in this statement are based on management\u2019s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx\u2019 program development activities, Amylyx\u2019 ability to execute on its commercial and regulatory strategy, regulatory developments, expectations regarding the timing of FDA and EMA review of AMX0035 for the treatment of ALS, market acceptance of AMX0035, Amylyx\u2019 ability to fund operations, and the impact that the ongoing COVID-19 pandemic will have on Amylyx\u2019 operations, as well as those risks and uncertainties set forth in Amylyx\u2019 United States Securities and Exchange Commission (SEC) filings, including Amylyx\u2019 Annual Report on Form 10-K for the year ended December 31, 2021, and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0 bwnowrap\" colspan=\"6\" rowspan=\"1\"><b>AMYLYX PHARMACEUTICALS, INC.<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"6\" rowspan=\"1\"><b>CONDENSED CONSOLIDATED BALANCE SHEETS<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"6\" rowspan=\"1\"><b>UNAUDITED<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"6\" rowspan=\"1\"><b>(in thousands)<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"6\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0\" colspan=\"2\" rowspan=\"1\"><b>June 30,<br \/>2022<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0\" colspan=\"3\" rowspan=\"1\"><b>December 31,<br \/>2021<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>Assets<\/b><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"3\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl6\" colspan=\"1\" rowspan=\"1\">Cash, cash equivalents and short-term investments<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0 bwnowrap\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 206,681\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 96,118\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl6\" colspan=\"1\" rowspan=\"1\">Prepaid expenses and other current assets<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 9,458\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5,392\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl6\" colspan=\"1\" rowspan=\"1\">Deferred offering costs<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u2014\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3,441\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl6\" colspan=\"1\" rowspan=\"1\">Other assets<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 9,101\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 663\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl10\" colspan=\"1\" rowspan=\"1\">Total assets<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 225,240\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 105,614\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>Liabilities, Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)<\/b><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"2\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"3\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl6\" colspan=\"1\" rowspan=\"1\">Accounts payable and accrued expenses<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25,377\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 17,396\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl6\" colspan=\"1\" rowspan=\"1\">Other liabilities<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7,074\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 35\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl10\" colspan=\"1\" rowspan=\"1\">Total liabilities<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 32,451\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 17,431\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl6\" colspan=\"1\" rowspan=\"1\">Redeemable convertible preferred stock<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u2014\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 239,351\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl6\" colspan=\"1\" rowspan=\"1\">Stockholders\u2019 equity (deficit)<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwnowrap\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 192,789\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0 bwnowrap\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (151,168\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl10\" colspan=\"1\" rowspan=\"1\">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwnowrap\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 225,240\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0 bwnowrap\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 105,614\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"2\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"2\" rowspan=\"1\"><\/td>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"17\" rowspan=\"1\"><b>AMYLYX PHARMACEUTICALS, INC.<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"17\" rowspan=\"1\"><b>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"17\" rowspan=\"1\"><b>UNAUDITED<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"17\" rowspan=\"1\"><b>(in thousands, except share and per share data)<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"17\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwnowrap\" colspan=\"7\" rowspan=\"1\"><b>Three Months Ended June 30,<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwnowrap\" colspan=\"7\" rowspan=\"1\"><b>Six Months Ended June 30,<\/b><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2021<\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\"><b>\u00a0<\/b><\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2021<\/b>\n<\/p>\n<\/td>\n<td class=\"bwalignc bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">Operating expenses:<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"3\" rowspan=\"1\"><\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"3\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"3\" rowspan=\"1\"><\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"3\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl4\" colspan=\"1\" rowspan=\"1\">Research and development<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 24,259\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10,929\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 45,723\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 17,793\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl4\" colspan=\"1\" rowspan=\"1\">General and administrative<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 29,994\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7,658\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 56,344\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 13,662\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl8\" colspan=\"1\" rowspan=\"1\">Total operating expenses<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 54,253\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 18,587\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 102,067\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 31,455\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">Loss from operations<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (54,253\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (18,587\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (102,067\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (31,455\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">Other income (expense), net<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 360\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (3,335\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 472\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (4,990\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">Loss before income taxes<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (53,893\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (21,922\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (101,595\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (36,445\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">Provision for income taxes<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 174\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u2014\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 320\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u2014\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0 bwsinglebottom bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">Net loss<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (54,067\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (21,922\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (101,915\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (36,445\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwsinglebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">Net loss per share attributable to common stockholders \u2014basic and diluted<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (0.93\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (3.41\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (1.85\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwpadl0\" colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0$\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (5.75\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwalignl bwvertalignt bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\">Weighted-average shares used in computing net loss per share attributable<br \/>\u00a0\u00a0 to common stockholders\u2014basic and diluted<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 58,275,903\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 6,433,889\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 54,958,537\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignl bwvertalignb bwrowaltcolor0 bwpadl0\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 6,334,813\n<\/p>\n<\/td>\n<td class=\"bwalignr bwvertalignb bwdoublebottom bwrowaltcolor0 bwpadl0 bwpadr0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n\u00a0\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media<\/b><br \/>Becky Gohsler<br \/>\n<br \/>Finn Partners<br \/>\n<br \/>(646) 307-6307<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;a&#x6d;&#x79;&#108;yx&#x6d;&#101;&#100;i&#x61;&#x74;&#101;a&#x6d;&#x40;&#97;&#109;y&#x6c;&#x79;&#120;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#97;&#x6d;&#121;&#x6c;y&#x78;m&#101;&#x64;&#105;&#x61;t&#x65;a&#109;&#x40;&#97;&#x6d;y&#x6c;y&#120;&#x2e;&#99;&#x6f;m<\/a>\n<\/p>\n<p>\n<b>Investors<\/b><br \/>Lindsey Allen<br \/>\n<br \/>Amylyx Pharmaceuticals, Inc.<br \/>\n<br \/>(857) 320-6244<br \/>\n<br \/><a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#73;&#110;&#x76;&#x65;&#x73;&#x74;&#x6f;&#x72;&#x73;&#64;amy&#108;&#121;&#120;&#46;&#99;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x49;&#x6e;&#x76;&#101;&#115;&#116;or&#x73;&#x40;&#x61;&#x6d;&#121;&#108;yx&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u02d7 ALBRIOZA\u2122 (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx \u02d7 FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial team now launch ready \u02d7 Marketing &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47213","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u02d7 ALBRIOZA\u2122 (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx \u02d7 FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial team now launch ready \u02d7 Marketing ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-11T20:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/21\/13268_Amylyx_logo_notagline-Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results\",\"datePublished\":\"2022-08-11T20:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/\"},\"wordCount\":1860,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005026\\\/en\\\/802420\\\/21\\\/13268_Amylyx_logo_notagline-Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/\",\"name\":\"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005026\\\/en\\\/802420\\\/21\\\/13268_Amylyx_logo_notagline-Color.jpg\",\"datePublished\":\"2022-08-11T20:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005026\\\/en\\\/802420\\\/21\\\/13268_Amylyx_logo_notagline-Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220811005026\\\/en\\\/802420\\\/21\\\/13268_Amylyx_logo_notagline-Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results - Pharma Trend","og_description":"\u02d7 ALBRIOZA\u2122 (also known as AMX0035) now commercially available in Canada, representing first product launch for Amylyx \u02d7 FDA Advisory Committee meeting to review new drug application for AMX0035 for the treatment of ALS scheduled for September 7, 2022; assigned PDUFA action date of September 29, 2022; U.S. commercial team now launch ready \u02d7 Marketing ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-11T20:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/21\/13268_Amylyx_logo_notagline-Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results","datePublished":"2022-08-11T20:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/"},"wordCount":1860,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/21\/13268_Amylyx_logo_notagline-Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/","url":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/","name":"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/21\/13268_Amylyx_logo_notagline-Color.jpg","datePublished":"2022-08-11T20:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/21\/13268_Amylyx_logo_notagline-Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220811005026\/en\/802420\/21\/13268_Amylyx_logo_notagline-Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/amylyx-pharmaceuticals-reports-second-quarter-2022-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47213"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47213\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47213"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47213"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}